DK0515144T3 - 1,3-oxathiolaner, der er nyttige ved behandling af hepatitis - Google Patents

1,3-oxathiolaner, der er nyttige ved behandling af hepatitis

Info

Publication number
DK0515144T3
DK0515144T3 DK92304530T DK92304530T DK0515144T3 DK 0515144 T3 DK0515144 T3 DK 0515144T3 DK 92304530 T DK92304530 T DK 92304530T DK 92304530 T DK92304530 T DK 92304530T DK 0515144 T3 DK0515144 T3 DK 0515144T3
Authority
DK
Denmark
Prior art keywords
treatment
hepatitis
oxathiolanes
useful
nucleoside analogues
Prior art date
Application number
DK92304530T
Other languages
Danish (da)
English (en)
Inventor
Nghe Nguyen-Ba
Bernard Belleau
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of DK0515144T3 publication Critical patent/DK0515144T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92304530T 1991-05-20 1992-05-19 1,3-oxathiolaner, der er nyttige ved behandling af hepatitis DK0515144T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110874A GB9110874D0 (en) 1991-05-20 1991-05-20 Medicaments

Publications (1)

Publication Number Publication Date
DK0515144T3 true DK0515144T3 (da) 2006-10-09

Family

ID=10695296

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92304530T DK0515144T3 (da) 1991-05-20 1992-05-19 1,3-oxathiolaner, der er nyttige ved behandling af hepatitis

Country Status (16)

Country Link
US (1) US5486520A (fr)
EP (1) EP0515144B1 (fr)
JP (3) JP3167788B2 (fr)
KR (1) KR100219958B1 (fr)
AT (1) ATE329598T1 (fr)
CA (1) CA2068943C (fr)
DE (1) DE69233631T2 (fr)
DK (1) DK0515144T3 (fr)
ES (1) ES2270413T3 (fr)
GB (1) GB9110874D0 (fr)
HK (1) HK1005542A1 (fr)
IE (1) IE921601A1 (fr)
IL (1) IL101836A (fr)
MX (1) MX9202374A (fr)
SG (1) SG47418A1 (fr)
ZA (1) ZA923477B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (fr) 1993-09-10 1995-03-16 Emory University Nucleosides a activite contre le virus de l'hepatite b
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
WO1996012716A1 (fr) * 1994-10-22 1996-05-02 Chong Kun Dang Corp. Derives nucleosidiques et leur procede de preparation
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP0831852B1 (fr) 1995-06-07 2006-11-29 Emory University Nucleosides ayant une activite anti-virus de l'hepatite b
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
CN1196701C (zh) 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
EP1535921A1 (fr) 1998-08-12 2005-06-01 Gilead Sciences, Inc. Procédé de préparation de 1,3-oxathiolanes nucléosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
DK1380303T3 (da) 1998-11-02 2008-12-01 Gilead Sciences Inc Kombinationsterapi til behandling af hepatitis B-virus
DK1140937T3 (da) 1998-12-23 2004-03-22 Shire Biochem Inc Antivirale nucleosid-analoger
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2405502A1 (fr) 2000-03-29 2001-10-04 Georgetown University Procede de traitement d'une infection virale par le virus de l'hepatite d
CA2308559C (fr) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones utiles pour la preparation d'analogues de nucleosides antiviraux
DK1389207T3 (da) 2001-03-01 2006-04-18 Gilead Sciences Inc Polymorfe og andre krystallinske former af cis-FTC
CA2351049C (fr) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires
ATE544453T1 (de) * 2002-07-15 2012-02-15 Gilead Sciences Inc Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
FR3136975A1 (fr) 2022-06-22 2023-12-29 L'oreal Composition d’éclaircissement des fibres kératiniques et procédé d’éclaircissement des fibres kératiniques mettant en œuvre cette composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591125B2 (en) * 1985-05-15 1989-11-30 Wellcome Foundation Limited, The Therapeutic nucleosides
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
CA1327000C (fr) * 1987-08-07 1994-02-15 David L.J. Tyrrell Therapie antivirale pour l'hepatite b
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
CA2055433A1 (fr) * 1989-05-15 1990-11-16 Jay H. Hoofnagle Methode de traitement de l'hepatite
WO1990014091A1 (fr) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Procede de traitement de l'hepatite
JP3164361B2 (ja) * 1989-06-27 2001-05-08 ザ ウエルカム ファウンデーション リミテッド 治療用ヌクレオシド
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
DE69232649T2 (de) * 1991-03-06 2002-11-28 Emory University, Atlanta Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides

Also Published As

Publication number Publication date
CA2068943A1 (fr) 1992-11-21
GB9110874D0 (en) 1991-07-10
KR100219958B1 (ko) 1999-09-01
EP0515144A1 (fr) 1992-11-25
ATE329598T1 (de) 2006-07-15
CA2068943C (fr) 2000-11-28
JPH11322608A (ja) 1999-11-24
IL101836A (en) 1997-03-18
AU1635192A (en) 1992-11-26
IE921601A1 (en) 1992-12-02
ZA923477B (en) 1993-01-27
DE69233631D1 (de) 2006-07-27
JP2001226268A (ja) 2001-08-21
MX9202374A (es) 1994-06-30
IL101836A0 (en) 1992-12-30
EP0515144B1 (fr) 2006-06-14
SG47418A1 (en) 1998-04-17
JP3167788B2 (ja) 2001-05-21
HK1005542A1 (en) 1999-01-15
ES2270413T3 (es) 2007-04-01
DE69233631T2 (de) 2007-05-24
JPH05202045A (ja) 1993-08-10
AU656961B2 (en) 1995-02-23
US5486520A (en) 1996-01-23
KR930019213A (ko) 1993-10-18

Similar Documents

Publication Publication Date Title
DK0515144T3 (da) 1,3-oxathiolaner, der er nyttige ved behandling af hepatitis
ATE138065T1 (de) Substituierte 1,3-oxathiolane mit antiviraler wirkung
DK0984013T3 (da) Antiviral aktivitet og opspaltning af 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolan
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
NZ228645A (en) 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
MA22144A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane .
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
NO2005017I2 (no) 1,3-Oksatiolan-nukleosidanaloger
NO2003001I2 (no) Valganciklovir
DK557087A (da) Forbindelse til behandling af retrovirusinfektioner
DK0675724T3 (da) Anvendelse af didesoxynucleosidanaloger til behandling af virale infektioner
DK0625158T3 (da) Terapeutiske nucleosider af 2',3'-dideoxy-3'-fluorpurinrækken
DK1380303T3 (da) Kombinationsterapi til behandling af hepatitis B-virus
PT97372A (pt) Processo de preparacao de ciclobutanos substituidos e de analogos de nucleosidos
BA96098A (bs) 1,3-Oksatiolanski nukleozidni analozi
BA96097A (bs) Supstituirani 1,3-oksatiolani s antivirusnim svojstvima